Epidemiological and

Pharmacoeconomic Aspects

of Alzheimer‘s Disease and

Dementia

United Nations Economic and Social Council 2000

Age Distribution of the World PopulationA

ge

male female

1950 2050

100

80

60

40

20

0male female

World Population Prospects, The 2002 Revision

Average Annual Growth Rates of the World Population

Pe

rce

nta

ge

(%)

4

3

2

1

0

-10–14

3.39

15–59 60+ 80+

Age

2.29

0.72

-0.04

Average Annual Growth (2000-2050 Medium variant)

Prevalence of DementiaP

reva

len

ce

Rat

e (%

)

25

20

15

10

5

065–69

23.6

70–74 75–79 80–84

Age

11.1

5.6

World (estimated)

85+

2.81.4

Jorm et al., Acta Psychiatrica Scandinavica 1987

Types of Dementia

Europe North America

Asia

Fratiglioni et al., Drugs Aging 1999

Alzheimer‘s disease Vascular dementia Other

61.4%27.6%

11.0%

74.5%10.0%

15.5%

46.5%38.1%

15.4%

Caregiver Costs Increase with Increasing Severity of Dementia (Germany)

An

nu

al C

os

ts (

€)

16,000

12,000

8,000

4,000

Community Setting Institutional Setting

Hallauer, 2002

MMSE26–21

MMSE20–15

MMSE14–10

MMSE<10

Diagnosis and Treatment Statistics of Alzheimer‘s Disease

On average AD patients live 8 to 10 years after diagnosis

AD can last for up to 20 years

treated with modern therapy< 6%

diagnosed (most in later stages)52%

treated9%

patients with AD in Europe~ 8 Mio.

Cognos Report, 2002

Potential Reduction in

Caregiver Time

Figure adapted according to references

Potential to Reduce Caregiver Time Increases with Severity of the Disease

30

mild moderate severe AD

MMSE Score20 10 0

7h/month (Donepezil)1

12h/month (Galantamine)2

52h/month (Memantine)3

1Dement Geriatr Cogn Disord 2003; Erratum 20032Chemical Business News Base 20013 Wimo et al., Pharmacoeconomics 2003

Specific Aspects of Moderate to Severe Alzheimer’s Diseases

Caregiver burden and cost of illness is high in patients

with moderate to severe AD

A treatment which is efficacious in these stages is

expected to reduce caregiver and societal cost

Memantine treatment has been shown to reduce

caregiver and societal costs (Wimo et al., 2003)